MLICM
ARQT icon

Metropolitan Life Insurance Company (MetLife)’s Arcutis Biotherapeutics ARQT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,431
Closed -$43.9K – 174
2024
Q1 		$43.9K Sell
4,431
-320
-7% -$2.39K ﹤0.01% 1471
2023
Q4 		$15.3K Buy
4,751
+1,932
+69% +$5.25K ﹤0.01% 2029
2023
Q3 		$15K Hold
2,819
– – ﹤0.01% 2029
2023
Q2 		$26.9K Buy
2,819
+1,063
+61% +$11.8K ﹤0.01% 1774
2023
Q1 		$19.3K Sell
1,756
-710
-29% -$10.3K ﹤0.01% 1900
2022
Q4 		$36.5K Hold
2,466
– – ﹤0.01% 1670
2022
Q3 		$47.1K Buy
2,466
+337
+16% +$7.64K ﹤0.01% 1495
2022
Q2 		$45.4K Buy
2,129
+424
+25% +$8.7K ﹤0.01% 1567
2022
Q1 		$32.8K Sell
1,705
-6,170
-78% -$104K ﹤0.01% 1831
2021
Q4 		$163K Hold
7,875
– – ﹤0.01% 2158
2021
Q3 		$188K Hold
7,875
– – ﹤0.01% 2122
2021
Q2 		$215K Buy
7,875
+2,215
+39% +$62.4K ﹤0.01% 2095
2021
Q1 		$164K Hold
5,660
– – ﹤0.01% 2157
2020
Q4 		$159K Hold
5,660
– – ﹤0.01% 2092
2020
Q3 		$166K Buy
5,660
+1,883
+50% +$50.3K ﹤0.01% 1899
2020
Q2 		$114K Hold
3,777
– – ﹤0.01% 2175
2020
Q1 		$113K Buy
+3,777
New +$101K ﹤0.01% 1958

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ARQT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 4,431 shares — an estimated $43.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ARQT in Q1 2020 and held it in 17 quarters. The position peaked at $215K in Q2 2021. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 4,431 Arcutis Biotherapeutics shares in Q2 2024, an estimated $43.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 17 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Arcutis Biotherapeutics position peaked at $215K in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.